Chugai Pharmaceutical (OTCMKTS:CHGCY) Sees Strong Trading Volume – Here’s What Happened

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) saw an uptick in trading volume on Friday . Approximately 128,203 shares changed hands during mid-day trading, a decline of 46% from the previous session’s volume of 239,306 shares.The stock last traded at $22.08 and had previously closed at $22.09.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CHGCY. Zacks Research raised shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. UBS Group lowered Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. Finally, The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Chugai Pharmaceutical has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 0.6%

The company has a market capitalization of $73.17 billion, a price-to-earnings ratio of 24.16 and a beta of 0.60. The stock’s 50-day simple moving average is $22.45 and its two-hundred day simple moving average is $25.67.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last released its earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. The business had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%. On average, sell-side analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.